Analysts at Oppenheimer started coverage on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set a "market perform" rating on the stock.

Other equities analysts also recently issued reports about the company. Piper Sandler increased their target price on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Sunday, January 8th. Needham & Company LLC assumed coverage on shares of Day One Biopharmaceuticals in a research report on Wednesday, December 14th. They issued a "buy" rating and a $40.00 price target for the company. HC Wainwright boosted their price objective on shares of Day One Biopharmaceuticals from $35.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, January 9th. The Goldman Sachs Group raised their target price on Day One Biopharmaceuticals from $45.00 to $62.00 and gave the stock a "buy" rating in a research report on Monday, January 9th. Finally, Bank of America assumed coverage on Day One Biopharmaceuticals in a report on Thursday, December 1st. They issued a "buy" rating and a $34.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $43.50.

Day One Biopharmaceuticals Stock Up 1.0 %

DAWN stock traded up $0.22 during midday trading on Thursday, reaching $21.75. The company had a trading volume of 740,620 shares, compared to its average volume of 676,846. Day One Biopharmaceuticals has a 1-year low of $5.44 and a 1-year high of $28.35. The stock has a 50 day moving average price of $21.34 and a 200-day moving average price of $21.20.

Insiders Place Their Bets

In other news, CEO Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $22.00, for a total value of $275,000.00. Following the completion of the sale, the chief executive officer now owns 1,181,486 shares in the company, valued at approximately $25,992,692. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Jeremy Bender sold 12,500 shares of the stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $22.00, for a total transaction of $275,000.00. Following the transaction, the chief executive officer now owns 1,181,486 shares of the company's stock, valued at approximately $25,992,692. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Samuel C. Blackman sold 10,000 shares of the business's stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $21.45, for a total value of $214,500.00. Following the completion of the sale, the insider now directly owns 1,260,148 shares of the company's stock, valued at $27,030,174.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 124,178 shares of company stock worth $2,638,412. Corporate insiders own 8.70% of the company's stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of large investors have recently modified their holdings of DAWN. Atlas Venture Life Science Advisors LLC raised its holdings in Day One Biopharmaceuticals by 9.3% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 8,968,305 shares of the company's stock worth $160,533,000 after buying an additional 766,667 shares during the last quarter. FMR LLC lifted its position in Day One Biopharmaceuticals by 163.1% in the 2nd quarter. FMR LLC now owns 6,826,574 shares of the company's stock valued at $122,196,000 after acquiring an additional 4,232,055 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its stake in Day One Biopharmaceuticals by 68.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,512,123 shares of the company's stock valued at $62,867,000 after purchasing an additional 1,425,674 shares during the last quarter. BlackRock Inc. increased its holdings in Day One Biopharmaceuticals by 29.5% during the 3rd quarter. BlackRock Inc. now owns 2,541,235 shares of the company's stock worth $50,901,000 after purchasing an additional 578,511 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of Day One Biopharmaceuticals by 59.8% in the second quarter. Franklin Resources Inc. now owns 2,465,380 shares of the company's stock worth $44,130,000 after purchasing an additional 922,521 shares during the last quarter. 86.08% of the stock is currently owned by institutional investors.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

See Also

• Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
• Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
• Mullen Automotive Stock Gains Momentum On Positive News
• Harley-Davidson Inc. Stock, Is It Time To Buy?
• The Bottom Is In For Meta Platforms, Volatility Is Not Over
• Analyzing Alaska Air's Recent Earnings

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.